New Publication: "The New Mexico Medical #Psilocybin Act and current trends in the United States psychedelic policy"

Affiliate Researcher Diego Borbón has published a new fully open access article in #Psychedelics (@Elsevier):

In April 2025 New Mexico enacted the Medical Psilocybin Act, the first legislated statewide medical psilocybin program in the United States, which places access in the hands of licensed clinicians for treatment-resistant depression, PTSD, substance use disorders and end-of-life care, and adds an advisory board, a treatment equity fund and a research fund. The article reviews the statute and situates it within a three-model typology of US psychedelic policy: decriminalization in Denver and Washington DC, regulated non-medical services in Oregon and Colorado, and clinician-governed medical programs in New Mexico, Utah, Texas and New Jersey. It also covers the federal turn marked by Executive Order 14401 of April 2026, the FDA's national priority vouchers for psilocybin candidates and its 2026 guidance on clinical investigations, along with parallels in Australia and New Zealand. The argument is that the clinician-governed model occupies a distinctive position, narrower than general legalization and broader than research-only pilots, though it also raises concerns about selection and assessment bias in provider-collected data and about the incentives to run randomized trials.